highly significantP < 0.0001
The median serum sCD163 in SLE patients was 12.3 ng/mL (IQR: 7.5–20.0), compared with 3.2 ng/mL (IQR: 3.0–3.8) in Non-SLE CKD patients, a difference that was highly significant ( P < 0.0001).
The median serum sCD163 in SLE patients was 12.3 ng/mL (IQR: 7.5–20.0), compared with 3.2 ng/mL (IQR: 3.0–3.8) in Non-SLE CKD patients, a difference that was highly significant ( P < 0.0001).
Additionally, in the current study, despite the significant positive correlation between urine sCD163 levels and SLEDAI scores in SLE patients (groups 1 and 2), the positive correlation between serum sCD163 and SLEDAI scores did not reach statistical significance, this finding can be explained by the inclusion of many factors other than kidney parameters in the SLEDAI grading criteria.